Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Value Growth And Long-Term Outlook
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market has experienced consistent expansion in recent years. Its value is projected to increase from $1.31 billion in 2025 to $1.37 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.6%. Historically, this growth has stemmed from factors such as a scarcity of targeted treatments, a dependence on traditional chemotherapy and radiation, insufficient knowledge of her2-positive gastric cancer, limited access to specialized medical facilities, and the gradual integration of immunotherapy.
The market size for human epidermal growth factor receptor 2 (her2)-positive gastric cancer is anticipated to show steady growth over the next few years. It is projected to expand to $1.64 billion in 2030, achieving a compound annual growth rate (CAGR) of 4.6%. This growth during the forecast period can be linked to the creation of new antibody-drug conjugates, a rise in clinical trials for her2-targeted therapies, improvements in healthcare infrastructure in developing markets, an increase in precision medicine and biomarker testing, and the proliferation of ambulatory surgery centers and specialized oncology clinics. Noteworthy trends for the forecast period include a greater embrace of her2-targeted therapies, increasing knowledge of gastric cancer subtypes, the wider use of immunotherapy and monoclonal antibodies, an expansion of personalized treatment methods, and a sharpened focus on early detection and diagnostic testing.
Get A Free Sample Report With In-Depth Market Insights:
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
Increased utilization of targeted cancer treatment is anticipated to drive expansion in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in the coming years. This therapy, also referred to as personalized medicine, involves a treatment strategy employing specific medications or agents to inhibit cancer cell proliferation by targeting distinct molecules crucial for tumor progression. Its increased application stems primarily from progress in genetic profiling, enabling more accurate treatments tailored to a patient’s unique tumor characteristics, thereby enhancing efficacy and reducing adverse effects. Specifically for HER2-positive gastric cancer, targeted therapy functions by directly assailing the HER2 protein, which is excessively present in these tumors, thereby decelerating disease advancement and improving patient results. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based professional membership body, reported that the Food and Drug Administration (FDA) sanctioned 16 novel personalized medicines in 2023, comprising 7 cancer drugs and 3 for diverse other ailments and conditions, marking a rise from 6 approvals in 2022. Consequently, the growing acceptance of targeted cancer therapy is fueling the expansion of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segments: Where Is Growth Concentrated?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Innovation Trends Shaping Future Development
Leading companies within the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are concentrating on securing regulatory approvals for novel treatments, such as sophisticated immunotherapy-enhanced combination regimens, which integrate immune checkpoint inhibitors with targeted therapy and chemotherapy, aiming to significantly enhance patient outcomes in initial treatment settings. This advanced immunotherapy-enhanced combination strategy utilizes the body’s immune system by disrupting programmed death (PD)-1 or programmed death (PD)-L1 interaction, concurrently targeting HER2 receptors, and employing chemotherapeutic agents, thereby boosting anti-tumor activity and improving survival rates. A notable example occurred in March 2025, when Merck & Co., Inc., a US-based biopharmaceutical company, gained approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), combined with trastuzumab and chemotherapy, for the first-line treatment of adults facing HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma where tumors express programmed death (PD)-L1. This recently approved combination regimen showed substantial improvements in both median progression-free survival and overall survival when benchmarked against conventional treatments. Achieving a superior overall response rate of 73% and a prolonged median duration of response, this therapy signifies a fundamental shift in the management of advanced HER2-positive gastric cancers.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Key Participants And Competitive Landscape
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
View The Full Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report:
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
